Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCO 116

Next Previous
Drug Profile

SCO 116

Alternative Names: KTX-101; KTX-1161; SCO-116

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SCOHIA PHARMA
  • Developer Kuria Therapeutics; SCOHIA PHARMA
  • Class Eye disorder therapies; Hepatoprotectants; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action NF-E2-related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Corneal injuries; Eye disorders; Fuchs' endothelial dystrophy; Lung disorders
  • Research Skin disorders
  • No development reported Diabetic nephropathies; Non-alcoholic steatohepatitis; Renal failure

Most Recent Events

  • 11 Sep 2025 Kuria Therapeutics receives SBIR grant from National Eye Institute (NEI) of the National Institutes of Health (NIH) for SCO 116 development in corneal endothelial disease and injury including Fuchs' endothelial dystrophy
  • 11 Sep 2025 Kuria Therapeutics announces intention to submit IND to US FDA for Fuchs' endothelial dystrophy
  • 11 Sep 2025 Kuria Therapeutics plans a phase II proof-of-concept trial for corneal endothelial disease and injury including Fuchs' endothelial dystrophy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top